https://www.taxtmi.com/caselaws?id=93332 Mannitol Injection B.P. 20% W/V was held not to be a patent or proprietary medicine for classification under sub-heading 3003.10 of Chapter 30. The label design, colour scheme and use of bars, by themselves, were insufficient to establish proprietary character. The decisive test was whether the container or packing carried distinctive marks or other indicia showing a connection with the manufacturer amounting to a proprietary interest. A medicine sold under a generic name does not become patent or proprietary merely because of branding features unless those features identify it as the manufacturer's special preparation. en-us Fri, 05 Mar 1999 00:00:00 +0530 Wed, 09 Nov 2011 18:55:12 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=93332 Mannitol Injection B.P. 20% W/V was held not to be a patent or proprietary medicine for classification under sub-heading 3003.10 of Chapter 30. The label design, colour scheme and use of bars, by themselves, were insufficient to establish proprietary character. The decisive test was whether the container or packing carried distinctive marks or other indicia showing a connection with the manufacturer amounting to a proprietary interest. A medicine sold under a generic name does not become patent or proprietary merely because of branding features unless those features identify it as the manufacturer's special preparation. Case-Laws Central Excise Fri, 05 Mar 1999 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=93332